Similar short-term efficacy of oral levosulpiride and intravitreal ranibizumab in patients with diabetic macular oedema

Fig. 1 Comparable improvements by 8-week oral levosulpiride (LSP) or intravitreal ranibizumab (RBZ) on the change from baseline in visual and structural parameters.Longitudinal changes from baseline in best-corrected visual acuity (BCVA) (A), central foveal thickness (CFT) (B), and mean macular volume (MMV) (C) after 8 weeks of treatment.Boxplots show median and individual values distribution of placebo (P, 18 eyes), LSP (22 eyes), and RBZ (16 eyes) groups.Statistical analysis was performed using one-way ANOVA-Sidak's multiple comparisons (A) or Kruskal-Wallis-Dunn's multiple comparisons (B, C) tests.*P < 0.05, ***P < 0.001, ns (non-significant).